share_log

Acelyrin | 8-K: ACELYRIN, INC. Announces Positive Phase 3 Data for Izokibep in Hidradenitis Suppurativa; Focuses Strategy on Lonigutamab and Reports Second Quarter 2024 Financial Results

Acelyrin | 8-K: ACELYRIN, INC. Announces Positive Phase 3 Data for Izokibep in Hidradenitis Suppurativa; Focuses Strategy on Lonigutamab and Reports Second Quarter 2024 Financial Results

Acelyrin | 8-K:ACELYRIN, INC.宣布Izokibep治疗化脓性汗腺炎的第三阶段数据为阳性;将战略重点放在Lonigutamab上,并公布2024年第二季度财务业绩
美股SEC公告 ·  08/13 16:18
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息